Canine visceral leishmaniasis biomarkers and their employment in vaccines

Publication date: Available online 20 May 2019Source: Veterinary ParasitologyAuthor(s): Rodolfo Cordeiro Giunchetti, Patricia Silveira, Lucilene Aparecida Resende, Jaqueline Costa Leite, Otoni Alves de Oliveira Melo-Júnior, Marina Luiza Rodrigues Alves, Laís Moreira Costa, Daniel Ferreira Lair, Vinícius Rossi Chaves, Ingrid dos Santos Soares, Ludmila Zanandreis de Mendonça, Mariana Ferreira Lanna, Helen Silva Ribeiro, Ana Alice Maia Gonçalves, Bruno Mendes Roatt, Rodrigo Dian Oliveira Aguiar-Soares, Juliana Vitoriano-Souza, Nádia das Dores Moreira, Fernando Augusto Siqueira Mathias, Jamille Mirelle de Oliveira CardosoAbstractThe natural history of canine visceral leishmaniasis (CVL) has been well described, particularly with respect to the parasite load in different tissues and immunopathological changes according to the progression of clinical forms. The biomarkers evaluated in these studies provide support for the improvement of the tools used in developing vaccines against CVL. Thus, we describe the major studies using the dog model that supplies the rationale for including different biomarkers (tissue parasitism, histopathology, hematological changes, leucocytes immunophenotyping, cytokines patterns, and in vitro co-culture systems using purified T-cells subsets and macrophages infected with L. infantum) for immunogenicity and protection evaluations in phases I and II applied to pre-clinical and clinical vaccine trials against CVL...
Source: Veterinary Parasitology - Category: Veterinary Research Source Type: research

Related Links:

This study was carried out in accordance with the recommendations of Institutional Review Board of the Federal University of Bahia, Brazil, with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Institutional Review Board of the Federal University of Bahia, Brazil (approval number 693.111). Human Blood Samples and Preparation of Peripheral Blood Cells Peripheral blood mononuclear cells (PBMC) were separated from heparinized venous blood by Ficoll-Hypaque gradient centrifugation. Cells were then washed in ...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
This study was performed in accordance with the ethical standards of the Institutional Animal Care and Use Committee (IACUC, approval FUA-007-14) from the Unidad de Biología Comparativa (UBA) at Pontificia Universidad Javeriana (PUJ, Bogotá, Colombia). All animal studies were conducted in accordance with the “Guide for the Care and Use of Laboratory Animals” from UBA-PUJ. The present study was described according to the Animal Research: Reporting in vivo Experiments (ARRIVE) criteria from the National Center for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (32). Mice ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions Nucleoside hydrolases are vital enzymes for the replication of Leishmania, conserved phylogenetic marker of the genus and strong-specific immunogens. We demonstrated that NH36 is an excellent target for chemotherapy of visceral leishmaniasis. Searching for the most immunogenic fraction of promastigotes of Leishmania we described the FML antigen of L. (L.) donovani, that has as its main component, the NH36 Nucleoside hydrolase. We developed second–generation vaccines with the FML and the NH36 native antigens, and with the NH36 recombinant protein. In addition, we obtained a third generation vaccine based ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In conclusion, we hope that this review brings about a new and more in-depth understanding of the part that Leishmania exosomes and various infectious agents play in the context of host-parasite interactions, with a particular focus on the establishment of infection. Future research in this field of investigations is critical for the development of new vaccine and diagnostic tools. Author Contributions The first draft was done by MO. AF and GD added new information. Funding Research in MO laboratory is supported by the Canadian Institute of Health Research (grant number: PJT-159765) and the Natural Sciences and Enginee...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Izabella Pereira da Silva Bezerra1†, Gabriel Oliveira-Silva1†, Danielle Sophia Ferreira Santos Braga1, Mirian França de Mello1, Juliana Elena Silveira Pratti1, Joyce Carvalho Pereira1, Alessandra Marcia da Fonseca-Martins1, Luan Firmino-Cruz1, Diogo Maciel-Oliveira1, Tadeu Diniz Ramos1, André Macedo Vale1, Daniel Claudio Oliveira Gomes2, Bartira Rossi-Bergmann1 and Herbert Leonel de Matos Guedes1,3* 1Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 2Núcleo de Doenças Infecciosas/Núcleo de Biotecnologia,...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Marcus Vinícius Alves-Silva1,2, Dirlei Nico1, Paula Melo de Luca3 and Clarisa B. Palatnik de-Sousa1,4* 1Laboratório de Biologia e Bioquímica de Leishmania, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 2Programa de Pós-Graduação em Biotecnologia Vegetal e Bioprocessos, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 3Laboratório de Imunoparasitologia, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil 4Faculdade...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Abstract An effective therapeutic vaccination strategy is required for controlling visceral leishmaniasis (VL), a fatal systemic disease, through boosting the immunosuppressed state in Leishmania-infected individuals, as the majority of them living in the endemic regions exhibit either subclinical or asymptomatic infection which further often develops into a full-blown disease. Previously in our laboratory, several Th1 stimulatory recombinant proteins were successfully cloned, purified and assessed for their prophylactic efficacy against Leishmania challenge. Due to their immunostimulatory property, these proteins...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Abstract American tegumentary leishmaniasis (ATL) is considered a neglected disease, for which an effective vaccine or an efficient diagnosis is not yet available and whose chemotherapeutic arsenal is threatened by the emergence of resistance by etiological agents such as Leishmania amazonensis. ATL is endemic in poor countries and has a high incidence in Brazil. Vaccines developed from native parasite fractions have led to the identification of defined antigenic subunits and the development of vaccine adjuvant technology. The purpose of the present study was to develop and compare preparations based on membrane a...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
In this study we evaluated how immune exhaustion, shown previously by our group to worsen in concert with VL progression, effected the capacity of vaccine candidate antigen/toll-like receptor (TLR) agonist combinations to promote protective CD4(+) T cell responses during progressive VL. In conjunction with Th1 responses, we also evaluated concomitant stimulation of immune-balanced IL-10 regulatory cytokine production by these vaccine products in progressive VL canine T cells. Vaccine antigen L111f in combination with TLR agonists significantly recovered CD4(+) T cell IFNγ intracellular production in T cells from asym...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Publication date: 30 August 2016 Source:Veterinary Parasitology, Volume 227 Author(s): Rosa M. Reguera, Miguel Morán, Yolanda Pérez-Pertejo, Carlos García-Estrada, Rafael Balaña-Fouce Canine leishmaniasis (CanL) is a parasite-borne disease mainly induced by Leishmania infantum in the Old World and Leishmania chagasi (infantum) in the New World. CanL is a zoonosis transmitted by the bite of infected Phlebotominae flies that act as vectors. CanL is a very serious disease that usually produces death when remains untreated and can be a focus of transmission to other dogs or humans. Infected dogs an...
Source: Veterinary Parasitology - Category: Veterinary Research Source Type: research
More News: Employment | Endemics | Hematology | HIV-Leishmania Co-infection | Men | Parasitic Diseases | Parasitology | Study | Vaccines | Veterinary Research | Veterinary Vaccinations